Nasus Pharma Faces Going Concern Doubt Amidst Clinical Development Push

Ticker: NSRX · Form: 20-F · Filed: Mar 25, 2026 · CIK: 0002029039

Complexity: moderate

Sentiment: bearish

Topics: Biotechnology, Pharmaceuticals, Clinical Stage, Going Concern, Drug Development, Intranasal Delivery, Epinephrine

TL;DR

**NSRX is burning cash with no revenue, and their going concern warning means this speculative biotech is a high-risk bet on future approvals.**

AI Summary

Nasus Pharma Ltd. (NSRX) is a clinical-stage specialty pharmaceutical company focused on intranasal drugs for emergency medical conditions. The company has not generated revenue from its continued activities and has incurred significant operating losses since its inception, anticipating continued losses for the foreseeable future. As of December 31, 2025, Nasus Pharma had 9,015,383 ordinary shares outstanding. The company's primary focus is on developing NS002, an Intranasal Epinephrine, and has paused development of NS001, an Intranasal Naloxone, seeking partnering opportunities. In November 2025, Nasus Pharma launched an additional Phase 2 study for NS002 in Canada, an open-label, fixed-sequence trial comparing NS002 to EpiPen in 50 healthy adults. They plan to initiate another Phase 2 study in Q2 2026 and a pivotal Phase 3 study in Q4 2026, with an IND submission for NS002 planned for Q3 2026. The company acknowledges that its current cash on hand is insufficient to fund projected operating requirements, raising substantial doubt about its ability to continue as a going concern. Significant risks include the lengthy and expensive clinical development process, the uncertainty of regulatory approval for NS002, and identified material weaknesses in internal control over financial reporting.

Why It Matters

Nasus Pharma's 20-F filing highlights critical financial instability, with the company acknowledging insufficient cash to fund operations, raising substantial doubt about its ability to continue as a going concern. This directly impacts investors, as the value of their investment is at significant risk if the company cannot secure additional financing or achieve profitability. For employees and customers, the future of the company's promising intranasal drug candidates, like NS002 for epinephrine delivery, hangs in the balance, potentially delaying or halting access to innovative emergency treatments. In the competitive pharmaceutical landscape, Nasus Pharma's struggle underscores the immense capital requirements and regulatory hurdles faced by clinical-stage biotechs, making it a cautionary tale for the broader market.

Risk Assessment

Risk Level: high — The risk level is high due to the company's explicit statement that it has not generated revenues, incurred significant losses since inception, and anticipates continued losses, which "raise a substantial doubt about our ability to continue as a going concern." Furthermore, the filing notes that current cash on hand is insufficient to fund projected operating requirements, indicating immediate financial pressure. The company also identified material weaknesses in its internal control over financial reporting, adding to operational and financial reporting risks.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Given the explicit 'going concern' warning and lack of revenue, new investors should avoid NSRX until the company demonstrates a clear path to sustainable funding and regulatory approval for its lead product, NS002. Existing investors should re-evaluate their position, understanding the significant risk of capital loss.

Financial Highlights

debt To Equity
N/A
revenue
$0
operating Margin
Negative (implied by losses)
total Assets
N/A
total Debt
N/A
net Income
Negative (implied by losses)
eps
N/A
gross Margin
N/A
cash Position
Insufficient (stated)
revenue Growth
N/A

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What is Nasus Pharma Ltd.'s primary product candidate?

Nasus Pharma Ltd.'s primary product candidate is NS002, an Intranasal Epinephrine, which is being developed for the treatment of emergency medical conditions.

Has Nasus Pharma Ltd. generated any revenue from its products?

No, Nasus Pharma Ltd. has not generated revenue from any product candidate and has incurred significant operating losses since its inception, anticipating continued losses for the foreseeable future.

What is the current financial outlook for Nasus Pharma Ltd.?

The current financial outlook for Nasus Pharma Ltd. is challenging, as the company does not believe its current cash on hand is sufficient to fund projected operating requirements, raising substantial doubt about its ability to continue as a going concern.

What stage of clinical development is NS002 in?

NS002 is currently in Phase 2 clinical development, with an additional Phase 2 study launched in Canada in November 2025 and another planned for Q2 2026. A pivotal Phase 3 study is planned for Q4 2026.

When does Nasus Pharma Ltd. plan to submit an IND application for NS002?

Nasus Pharma Ltd. plans to submit an Investigational New Drug (IND) application for NS002 in the third quarter of 2026, following the completion of additional Phase 2 studies.

What are the key risks highlighted in Nasus Pharma Ltd.'s 20-F filing?

Key risks include the company's inability to generate revenue, significant operating losses, insufficient cash to fund operations raising going concern doubt, and identified material weaknesses in internal control over financial reporting.

How many ordinary shares of Nasus Pharma Ltd. were outstanding as of December 31, 2025?

As of December 31, 2025, there were 9,015,383 ordinary shares of Nasus Pharma Ltd. outstanding.

What is Nasus Pharma Ltd.'s strategy for NS001, Intranasal Naloxone?

Nasus Pharma Ltd. has paused the development of NS001, Intranasal Naloxone, and is planning to pursue partnering opportunities for its further development.

What accounting standards does Nasus Pharma Ltd. use for its financial statements?

Nasus Pharma Ltd. reports its financial statements in accordance with generally accepted accounting principles in the United States, or U.S. GAAP.

What is the significance of the 'going concern' warning for Nasus Pharma Ltd. investors?

The 'going concern' warning indicates that there is substantial doubt about Nasus Pharma Ltd.'s ability to continue operations without securing additional financing, posing a significant risk of capital loss for investors.

Risk Factors

Industry Context

The specialty pharmaceutical sector is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies often focus on niche therapeutic areas or novel delivery mechanisms, like Nasus Pharma's intranasal approach. The competitive landscape includes established pharmaceutical giants and numerous clinical-stage biotechs, all vying for market share and investor capital.

Regulatory Implications

Nasus Pharma faces significant regulatory risks, primarily concerning the approval of NS002. The lengthy and expensive clinical trial process, coupled with the uncertainty of FDA approval, poses a substantial barrier. Any delays or failures in the regulatory pathway for NS002 could severely impact the company's ability to generate revenue and continue operations.

What Investors Should Do

  1. Monitor NS002 clinical trial progress and regulatory submissions.
  2. Assess the company's ability to secure additional funding.
  3. Evaluate the effectiveness of internal control remediation efforts.
  4. Consider the long-term viability given the lack of revenue and ongoing losses.

Key Dates

Glossary

Clinical-stage pharmaceutical company
A company focused on developing drugs that are currently undergoing clinical trials to test their safety and efficacy in humans. (Indicates Nasus Pharma has not yet brought a product to market and relies heavily on R&D success.)
Intranasal drugs
Medications delivered through the nasal cavity, often designed for rapid absorption into the bloodstream. (This is Nasus Pharma's core technology platform for its product candidates like NS002.)
Going concern
A business's ability to continue operating for the foreseeable future without the threat of liquidation. (Nasus Pharma's financial situation raises substantial doubt about its ability to continue as a going concern.)
Material weakness
A deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. (Identified material weaknesses in Nasus Pharma's financial reporting controls pose a significant risk.)
IND submission
Investigational New Drug application, a request submitted to the FDA to seek permission to administer an investigational drug to humans. (The planned IND submission for NS002 in Q3 2026 is a key regulatory milestone.)
Pivotal Phase 3 study
A large-scale clinical trial designed to confirm the efficacy and safety of a drug for its intended use, typically required for regulatory approval. (The planned Phase 3 study for NS002 is essential for seeking marketing approval.)

Year-Over-Year Comparison

Information for comparison to a previous filing is not available in the provided text. However, the current filing highlights ongoing significant operating losses, insufficient cash for projected needs, and substantial doubt about the ability to continue as a going concern. The company is actively advancing NS002 through Phase 2 trials with planned regulatory submissions and pivotal studies in 2026, indicating continued development efforts despite financial challenges.

Filing Stats: 4,520 words · 18 min read · ~15 pages · Grade level 12.8 · Accepted 2026-03-25 09:14:01

Key Financial Figures

Filing Documents

Item 18

Item 17 Item 18 If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No TABLE OF CONTENTS Page INTRODUCTION iii CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS iii SUMMARY RISK FACTORS 1 PART I 1 ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 1 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 1 ITEM 3. KEY INFORMATION 1 A. [Reserved] 1 B. Capitalization and Indebtedness 1 C. Reasons for the Offer and Use of Proceeds 1 D.

Risk Factors

Risk Factors 1 ITEM 4. INFORMATION ON THE COMPANY 50 A. History and Development of the Company 50 B. Business Overview 51 C. Organizational Structure 101 D. Property, Plants and Equipment 101 ITEM 4.A UNRESOLVED STAFF COMMENTS 101 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 102 A. Operating Results 102 B. Liquidity and Capital Resources 105 C. Research and development, patents and licenses, etc. 107 D. Trend Information 107 E. Critical Accounting Estimates 108 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 110 A. Directors and Senior Management 110 B. Compensation 113 C. Board Practices 117 D. Employees 130 E. Share Ownership 130 F. Disclosure of a Registrant's Action to Recover Erroneously Awarded Compensation 132 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 132 A. Major Shareholders 132 B. Related Party Transactions 134 C. Interests of Experts and Counsel 138 ITEM 8. FINANCIAL INFORMATION 138 A. Consolidated Statements and Other Financial Information 138 B. Significant Changes 138 ITEM 9. THE OFFER AND LISTING 138 A. Offer and Listing Details 138 B. Plan of Distribution 139 C. Markets 139 D. Selling Shareholders 139 E.

Dilution

Dilution 139 F. Expenses of the Issuer 139 i ITEM 10. ADDITIONAL INFORMATION 139 A. Share Capital 139 B. Memorandum and Articles of Association 139 C. Material Contracts 139 D. Exchange Controls 139 E. Taxation 140 F. Dividends and Paying Agents 145 G. 145 H. Documents on Display 145 I. Subsidiary Information 146 J. Annual Report to Security Holders 146 ITEM 11.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 146 ITEM 12.

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES 146 A. Debt Securities 146 B. Warrants and rights 146 C. Other Securities 146 D. American Depositary Shares 146 PART II 147 ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES 147 ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS 147 ITEM 15.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 147 ITEM 16. [RESERVED] 147 ITEM 16. A AUDIT COMMITTEE FINANCIAL EXPERT 147 ITEM 16. B CODE OF ETHICS 148 ITEM 16. C PRINCIPAL ACCOUNTANT FEES AND SERVICES 148 ITEM 16. D EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES 149 ITEM 16. E PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS 149 ITEM 16. F CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT 149 ITEM 16. G CORPORATE GOVERNANCE 149 ITEM 16. H MINE SAFETY DISCLOSURE 150 ITEM 16. I DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 150 ITEM 16. J INSIDER TRADING POLICIES 150 ITEM 16 K CYBERSECURITY 150 PART III 151 ITEM 17.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 151 ITEM 18.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 151 ITEM 19. EXHIBITS 151

SIGNATURES

SIGNATURES 152 ii Nasus Pharma Ltd. INTRODUCTION We are a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. Intranasal administration is especially suitable for medical emergencies when prompt drug administration is critical, since the nose is lined up with a very rich vascular bed enabling quick drug absorption. We are developing a unique powder-based intranasal, or PBI, technology with a specialized product portfolio to address acute medical conditions and public health threats. We believe that PBI may be superior over liquid-based solutions due to potentially significantly higher dispersion of powder throughout the nasal cavity, thus creating a larger absorption area and enabling more rapid and higher drug absorption. In addition, the uniform spherical powder particles of our proprietary formulation may enhance the consistency and reliability of the delivered dose. The initial clinical trials of our PBI products involving different molecules performed thus far have demonstrated quicker and higher drug absorption over similar solution-based nasal products. However, to date we have only tested our product candidates on a relatively small patient population and none of our products have been approved by the U.S. Food and Drug Administration, or the FDA. Prior to obtaining FDA approval of any of our product candidates, we will need to perform additional clinical testing of our product candidates to confirm any benefits and advantages our products may have over similar nasal products. Our mission is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective, user-friendly and immediately active PBI specialized products. To help achieve this we are focused on developing NS002, an Intranasal Epinephrine, and we have also been developing NS001, an Intranasal Naloxone, which we have paused, planning to pursue partnering op

Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will,"

Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" "intends" or "continue," or the negative of these terms or other comparable terminology. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition, expected capital needs and expenses, statements relating to the research, development, completion and use of our products, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. iii Forward-looking on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking the regulatory pathways that we may elect to utilize in seeking EMA, FDA and other regulatory approvals; obtaining EMA and FDA approval of, or other regulatory action in Europe or the United States and elsewhere with respect to Intranasal Epinephrine, Intranasal Naloxone or other product candidates that we may seek to develop; the commercial launch and future sales of Intranasal Epinephrine or any other future product candidates; our expectations regarding the timing of commencing further clinical trials, the process entailed in conducting each such tri

Risk Factors

Risk Factors The risk factors described below are a summary of the principal risk factors associated with an investment in us. These are not the only risks we face. You should carefully consider these risk factors, together with the section entitled "Risk Factors" set forth in Item 3.D, of this annual report on Form 20-F. 1 Risks Related to Our Financial Position and Capital Requirements We have not generated revenues from our continued activities, have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability, which raise a substantial doubt about our ability to continue as a going concern and could prevent us from obtaining new financing on reasonable terms or at all. We are a clinical stage pharmaceutical company and we have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future. We have not generated revenue from any product candidate and may never be profitable, even if we receive regulatory approval to commercialize our products. We do not believe that our current cash on hand will be sufficient to fund our projected operating requirements. This raises substantial doubt about our ability to continue as a going concern. We have identified material weaknesses in our internal control over financial reporting. If our remediations are not effective, or if we experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately or timely report our financial conditions or results or operations, or prevent fraud, which may adversely affect investor confidence in our Company and as a result, the market price of our Ordinary Shares. Risks Related to Product Development, Regulatory Approval and Commercialization We depend substantially

View Full Filing

View this 20-F filing on SEC EDGAR

View on Read The Filing